TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3500-3507

  Qureshi, K N ^a   Griffiths, T R L ^b   Robinson, M C ^c   Marsh, C ^c   Roberts, J T ^d   Hall, R R ^c   Lunec, J ^b   Neal, D E ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c FREEMAN HOSPITAL   (United Kingdom)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; METHOTREXATE; SUPPRESSOR FACTOR; SUPPRESSOR FACTOR TP53; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER INHIBITION; CANCER INVASION; DIAGNOSTIC APPROACH ROUTE; DRUG ACCUMULATION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TRANSURETHRAL RESECTION; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, MULTIPLE; EPIRUBICIN; FEMALE; GENES, P53; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 0032713930     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Anderstøm, C., Johansson, S., and Nilsson, S. The significance of lamina propria invasion on the prognosis of patients with bladder cancer. J. Urol., 124: 23-26, 1980.
2. Frazier, H. A., Robertson, J. E., Dodge, R. K., and Paulson, D. F. The value of pathologic factors in predicting cancer specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer (Phila.), 71: 3993-4001, 1993.
3. Pagano, F., Bassi, P., Galetti, T. P., Meneghini, A., Milani, C., Artibani, W., and Garbeglio, A. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumour, nodes and metastases classification. J. Urol., 145: 45-50, 1991.
4. Soloway, M. S., Ikard, M., and Ford, K. Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer (Phila.), 47: 476-480, 1981.
5. Oliver, R. T., Newlands, E. S., Wiltshaw, E., and Malpas, J. S. A phase 2 study of cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group. Br. J. Urol., 53: 444-447, 1981.
6. Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Ahmed, T., Weiselberg, L. R., Geller, N., Hollander, P. S., Herr, H. W., Sogani, P. C., Morse. M. J., and Whitmore, W. F. Preliminary results of MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 133: 403-407, 1985.
7. Harker, W. G., Meyers, F. J., Freiha, F. S., Palmer, J. M., Shortliffe, L. D., Hannigan, J. F., McWhirter, K. M., and Torti, F. M. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group Study. J. Clin. Oncol., 3: 1463-1470, 1985.
8. Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., Lowe, B. A., Blumenstein, B., and Trump, D. A randomised comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol., 10: 1066-1073, 1992.
9. Donat, S. M., Herr, H. W., Bajorin, D. F., Fair, W. R., Sogani, P. C., Russo, P., Sheinfeld, J., and Scher, I. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J. Urol., 156: 368-371, 1996.
10. Esrig, D., Spruck, C. H., Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S. C., Skinner, D. G., Jones, P. A., and Cote, R. J. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol., 143: 1389-1397, 1993.
11. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E., and Pellicer, A. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347-353, 1994.
12. Vet, J. A., Bringuier, P. P., Schaafsma, H. E., Witjes, J. A., Debruyne, F. M., and Schalken, J. A. Comparison of p53 protein overexpression with p53 mutation in bladder cancer: clinical and biologic aspects. Lab. Invest., 73: 837-843, 1995.
13. Abdel-Fattah, R., Challen, C., Griffiths, T. R. L., Robinson, M. C., Neal, D. E., and Lunec, J. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br. J. Cancer, 77: 2230-2238, 1998.
14. Spruck, C. H. R., Ohneseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Miyao, N., Tsai, Y. C., Lerner, S. P., Schmutte, C., Yang, A. S., Cote, R., Dubeau, L., Nichols, P. W., Hermann, G. G., Steven, K., Horn, T., Skinner, D. G., and Jones, P. A. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784-788, 1994.
15. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
16. Kuczyk, M. A., Bokemeyer, C., Serth, J., Hervatin, C., Oelke, M., Hofner, K., Tan, H. K., and Jonas, U. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur. J. Cancer, 31A: 2243-2247, 1995.
17. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., and Skinner, D. G. p53 and treatment of bladder cancer. Nature (Lond.), 385: 123-124, 1997.
18. Lowe, S. W., and Jacks, T. p53 and treatment of bladder cancer. Nature (Lond.), 385: 123-124, 1997.
19. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., Jr., and Kohn, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997.
20. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C., and Scher, H. I. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13: 1384-1390, 1995.
21. Herr, H. W., Bajorin, D. F., Scher, H. I., Cordon-Cardo, C., and Reuter, V. E. Can p53 help select patients with invasive bladder cancer for bladder preservation. J. Urol., 161: 20-23, 1999.
22. Skinner, D. G., Daniels, J. R., Russell, C. A., Lieskovsky, G., Boyd, S. D., Nichols, P., Kern, W., Sakamoto, J., Krailo, M., and Groshen, S. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol., 145: 459-464, 1991.
23. Sengeløv, L., Horn, T., and Steven, K. p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J. Cancer Res. Clin. Oncol., 123: 565-570, 1997.
24. Hall, R. R., and Roberts, J. T. Neoadjuvant chemotherapy, a method to conserve the bladder. Proc. Eur. Soc. Cancer, 27: 2, 1991.
25. Union Internationale Contre le Cancer. TNM classification of malignant tumours. Hermaneck, P., and Sobin, L. H. Heidelberg: Springer-Verlag, 1992.
26. Mostofi, F. International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer (Phila.), 33: 1480-1484, 1973.
27. Kaplan, E. L., and Meier, P. Nonparametric estimations from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
28. Cox, D. R. Partial likelihood. Biometrika, 62: 269-279, 1975.
29. Herr, H. W., Bajorin, D. F., and Scher, H. I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: tenyear outcome. J. Clin. Oncol., 16: 1298-1301, 1998.
30. Waldman, T., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature (Lond.), 381: 713-716, 1996.
31. Droller, M. J. Adjuvant chemotherapy following cystectomy for invasive bladder cancer. J. Urol., 145: 465, 1991.
32. Wu, S. C., Pollack, A., Czerniak, B., Chyle, V., Zagars, G. K., Dinney, C. P., Hu, S. X., and Benedict, W. F. Prognostic value of p53 in muscle-invasive bladder cancer treated with preoperative radiotherapy. Urology, 47: 305-310, 1996.
33. Shipley, W. U., Zietman, A. L., Kaufman, D. S., Althausen, A. F., and Heney, N. M. Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation. Int. J. Radiat. Oncol. Biol. Phys., 39: 937-943, 1997.
34. Serretta, V., Lo-Greco, G., Pavone, C., and Pavone-Macaluso, M. The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy: 10-year experience. J. Urol., 159: 1187-1191, 1998.